ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2679

Early-Life Nutrition and Gene-Environment Interactions Influencing Juvenile Idiopathic Arthritis Risk: Results from a Pregnancy Cohort
Abstract Number: 2680

High Health Care Utilization Preceding Diagnosis of Juvenile Idiopathic Arthritis
Abstract Number: 2681

Derivation and Validation of Inflammation-Adjusted Lipid Measures to Improve Cardiovascular Risk Prediction in Rheumatoid Arthritis
Abstract Number: 2682

Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
Abstract Number: 2683

Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Abstract Number: 2684

Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
Abstract Number: 2685

Assessing for Racial/Ethnic Variability in U.S.-FRAXTM Performance Among Older Adult Women with Rheumatoid Arthritis in the United States
Abstract Number: 2686

Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Abstract Number: 2687

Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
Abstract Number: 2688

Single cell RNA-seq immune profiling of blood samples from a psoriatic disease clinical trial reveals a CD4 T cell population associated with response to IL-23 blockade
Abstract Number: 2689

Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
Abstract Number: 2690

Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
Abstract Number: 2691

Understanding the Impact of Overweight and Obesity on Treatment Response in Psoriatic Arthritis: Results from a Longitudinal Cohort Study
Abstract Number: 2692

Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA)
Abstract Number: 2693

CAR T-cell Therapy in SLE: A Systematic Review

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].